MSC Secretome Compositions for Perianal Fistula Treatment
Summary
USPTO granted Patent US12590310B2 to Direct Biologics, LLC for methods of treating perianal fistula using bone marrow-derived MSC secretome products. The patent claims compositions produced under specific hypoxic conditions (below 5% oxygen tension) and acidic pH (below 7). The B2 patent grant contains 18 claims.
What changed
USPTO granted Patent US12590310B2 to Direct Biologics, LLC covering methods of treating perianal fistula using bone marrow-derived MSC secretome products cultured under hypoxic conditions (below 5% oxygen tension) and acidic pH (below 7). The patent contains 18 claims with application number 17920997.
Patent holders should ensure proper patent marking and review maintenance fee schedules. Healthcare providers and pharmaceutical companies developing similar cell-based or secretome products should assess potential infringement risks. No immediate compliance action is required for entities not involved in this technology area.
Source document (simplified)
Methods and compositions for treating inflammatory conditions associated with infectious disease
Grant US12590310B2 Kind: B2 Mar 31, 2026
Assignee
DIRECT BIOLOGICS, LLC
Inventors
Kenneth Allen Pettine, Kevin Hicok, Timothy Alexander Moseley
Abstract
Disclosed are methods of treating perianal fistula a subject by administering a therapeutic MSC secretome product made by a method comprising culturing bone marrow-derived MSCs under conditions that include oxygen tension below 5% and a culture media with a pH below 7.
CPC Classifications
A61K 9/127 A61K 38/1709 A61K 38/177 A61K 45/06
Filing Date
2021-04-22
Application No.
17920997
Claims
18
Named provisions
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when ChangeBridge: Patent Grants - Pharma (A61K) publishes new changes.